Stock Financial Ratios, Dividends, Split History

AMOT / Allied Motion Technologies, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price47.61
Volume30,800.00
Market Cap ($M)460.62
Enterprise Value ($M)510.55
Book Value ($M)95.11
Book Value / Share10.03
Price / Book4.84
NCAV ($M)-19.53
NCAV / Share-2.06
Price / NCAV-23.58
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 9,153,000
Common Stock Shares Outstanding 9,427
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Diluted Shares Outstanding 9,275,000
Common Shares Outstanding 9,426,984
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.06
Return on Assets (ROA)0.04
Return on Equity (ROE)0.11
Balance Sheet (mrq) ($M)
Assets214.77
Liabilities119.66
Quick Ratio1.55
Current Ratio2.57
Income Statement (mra) ($M)
Sales Revenue Goods Net252,012,000.00
Operating Income18.80
Net Income8.04
Earnings Per Share Diluted0.87
Earnings Per Share Basic0.88
Cash Flow Statement (mra) ($M)
Cash From Operations25.41
Cash from Investing-6.20
Cash from Financing-6.20
Identifiers and Descriptors
CUSIP019330109
Central Index Key (CIK)46129

Split History

Stock splits are used by Allied Motion Technologies, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

8h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

9h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

ST or AMOT: Which Is the Better Value Stock Right Now?

2018-06-12 zacks
Investors interested in stocks from the Instruments - Control sector have probably already heard of Sensata (ST - Free Report) and Allied Motion Technologies (AMOT - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. (5-0)

Top Ranked Momentum Stocks to Buy for June 11th

2018-06-11 zacks
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 11th: (15-0)

New Strong Sell Stocks for June 6th

2018-06-06 zacks
Access National Corporation (ANCX - Free Report) is the owner and operator of a bank holding company. The Zacks Consensus Estimate for its current year earnings has been revised 5.3% downward over the last 60 days. (15-0)

Moving Average Crossover Alert: Allied Motion Technologies, Inc. (AMOT)

2018-06-06 zacks
Allied Motion Technologies, Inc. (AMOT - Free Report) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for AMOT broke out above the 200 Day Simple Moving Average, suggesting a short-term bullish trend. (60-0)

AstroNova, Inc. (ALOT) CEO Gregory Woods on Q1 2019 Results - Earnings Call Transcript

2018-06-05 seekingalpha
Good day, everyone, and welcome to AstroNova’s First Quarter Fiscal Year 2019 Earnings Conference Call. Today’s conference is being recorded. (4-0)

CUSIP: 019330109